Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111536 | 0.69 | MAOA (0.46) | MAOAMAOBGAANPSR1 | |
| SCHEMBL3690493 | 0.69 | MAOA (0.59) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| SCHEMBL29453995 | 0.68 | MAOA (0.64) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| SCHEMBL10462577 | 0.66 | MAOA (0.73) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| Xanthene SCHEMBL29378346 | 0.65 | MAOA (1.00) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| Xanthene SCHEMBL30586075 | 0.65 | MAOA (1.00) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| Xanthene SCHEMBL9339684 | 0.65 | MAOA (1.00) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| Xanthene SCHEMBL4267 | 0.65 | MAOA (1.00) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| Xanthene SCHEMBL27493963 | 0.65 | MAOA (1.00) | MAOAMAOBMAPKAPK2NPC1LMNA | |
| SCHEMBL13777197 | 0.64 | MAOA (0.63) | MAOAMAOBMAPKAPK2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140120564-A1 | NON-INVASIVE MEASUREMENT OF ANALYTES | CERCACOR LABORATORIES, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8509867-B2 | Non-invasive measurement of analytes | CERCACOR LABORATORIES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20070020181-A1 | Non-invasive measurement of analytes | CERCACOR LABORATORIES, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2004044557-A2 | NON-INVASIVE MEASUREMENT OF ANALYTES | ARGOSE, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070020181-A1 | Non-invasive measurement of analytes | SLC2A3, SLC2A2, SLC2A4 | MAOA 3528/4885MAOB 3740/4885MAPKAPK2 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.